Our results support previous reports that demonstrate inhibition of NAFLD pathogenesis including the down-regulation of lipogenesis markers, SREBP-1c, FASN and ACC1, and up-regulation of the lipid oxidation marker, PPARα [24]. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.